Updates on Clinical Commissioning Work Programs in England

04

Jun 2021

On May 17, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering the period January 20, 2021 - April 20, 2021).

Two types of Work Programmes exist:

  • Clinical commissioning policy work program;
  • Specialized commissioning service specification work program.

Updates were only made in the clinical commissioning policy work program.

One new med-tech related Clinical Commissioning Policy was added to the work program: Ultra-hypofractionated radiotherapy using five treatments for men with low or intermediate-risk localized prostate cancer.

Four new med-tech related policies were published:

The development of two med-tech related policies was discontinued:

  • TAVI and surgical valve replacement for aortic stenosis - the commissioning position with Shared Decision Making Tool was proposed instead;
  • Extracorporeal photopheresis (ECP) for treatment of chronic lung allograft dysfunction (CLAD). The following reasons were provided: a grant from the National Institute of Health Research (NIHR) has been awarded to evaluate ECP in NHS CLAD populations in a randomized control trial (ECLAD); the Internal Medicine Programme of Care (POC) supports the decision for the policy work to be stopped at this point without not-for-routine commissioning (NRC) position; this follows the broader discussion with the Clinical Director for the policy team, clinical lead, and key stakeholders; the rationale was that ECP is an existing service across a wider patient group. It could potentially destabilize existing services to take forward an NRC policy in advance of the findings from the ECLAD trial.

The status of ongoing policies was updated as well.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

22

Jun 2021

In late May 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, has published Bulletins 0177 and 0074 with changes to be implemented not later than August 01, 2021. Five new procedure codes related to diagnostic imaging, ENT, breast reconstruction, and gynecology, and nine new diagnostic codes were introduced.

Read more

18

Jun 2021

In May 2021, the National Institute for Health and Care Excellence (NICE) published five new Interventional Procedure Guidance (ex-situ machine perfusion for extracorporeal preservation of lungs for transplant, transvaginal laser therapy for stress urinary incontinence and for urogenital atrophy, electrohydraulic lithotripsy for difficult-to-treat bile duct stones, and permanent His-bundle pacemaker for heart failure), one new Medical Technologies Guidance (UroLift for benign prostatic hyperplasia), and two new Medtech Innovation Briefings (Axonics sacral neuromodulation system for faecal incontinence and KODEX-EPD for cardiac imaging during ablation of arrhythmias). Also, three clinical guidelines and two Medical Technologies Guidance were updated.

Read more

17

Jun 2021

In late May 2021, the Treatment Council (Behandlingsråd), a new framework for assessing treatments and health technologies in Denmark, started accepting applications for the assessment of health technologies.

Read more

16

Jun 2021

The Health Sciences Institute in Aragon (IACS) systematically evaluates healthcare technologies and facilitates the promotion of research, effective innovation, and decision-making in health services through knowledge management. Currently, the IACS is working on assessments of efficacy, effectiveness, and safety of intraoperative radiation therapy in breast cancer, determination of preeclampsia biomarkers SFlt-1 and PlGF, treatment of congenital ventricular septal defect by cardiac catheterization, and others.

Read more

15

Jun 2021

The National Institute for Health and Care Excellence (NICE) is currently developing health technology assessments concerning in-vitro diagnostics in its Diagnostic Guidance and Medtech Innovation Briefing programs. As of June 08, 2021, there are ten ongoing assessments.

Read more